Introduction
Advances in the treatment of Parkinsonism over the last decade have significantly improved the morbidity from this condition and also changed the natural history of the disease. These improvements have, of course, resulted from the introduction of a succession of new forms of medical treatment levodopa, amantadine, decarboxylase inhibitors and finally synthetic dopamine agonists-and it has become difficult for the medical profession always to remain up to date with the latest development. There are problems about when to introduce treatment, what drugs to use in combination, how to treat side effects and what benefits can be expected from any drug combination. In this paper the author attempts to review the current position regarding treatment together with a short discussion of probable advances in the future.
Diagnosis
Of great importance in the treatment of Parkinson's disease is firstly the distinction of symptomatic cases from idiopathic Parkinsonism. It The patient, therefore, has to be assessed at the time of diagnosis and there are three main considerations that apply (Table 1) . The therapeutic effects of levodopa with or without a decarboxylase inhibitor are the same, but the addition of a decarboxylase inhibitor allows for a reduced dose of levodopa, probably a more rapid response, a 'smoother' therapeutic response with less diurnal fluctuation and, most importantly, a reduction in the peripheral side effects of levodopa. Marsden and his co-workers demonstrated (Marsden et al., 1973 ) the considerable reduction in incidence of peripheral side effects, especially nausea and vomiting, and it is the absence of this side effect that makes 'Sinemet' or 'Madopar' better tolerated over a longer period of time than levodopa alone.
Levodopa is absorbed and metabolized rapidly. Thus it should be administered 3-or 4-hourly and some patients benefit from even more frequent dosage.
The action of levodopa is on all the manifestations of Parkinson's disease but hypokinesia and the resulting functional disability show the greatest response. Rigidity is greatly improved in the majority of patients, and tremor significantly reduced in a minority. Disturbance of gait and of posture may be dramatically relieved. There is seldom much improvement in dysarthria or dysphonia. Using combined preparations the response is rarely delayed more than a few weeks, although it may take time for the patient to learn to take full advantage of the benefits that treatment has produced.
In about 20% of patients the effect of levodopacontaining treatment is dramatic so that there may be scarcely any detectable features of Parkinsonism.
In about 50%4 of patients the improvement, while judged 'moderate' or 'slight', may be sufficient to make the critical difference between independence and dependency.
Dosage should be started low and increased on alternate days or twice weekly until an optimum therapeutic response has been achieved, or side effects develop.
Levodopa should normally be given, in the moderate or severely afflicted case, in association with the second important group of drugs-the anticholinergics. This is because, as Hughes showed in 1971 (Hughes et al., 1971) 
Other agents
Amantadine has a similar range of therapeutic effect to levodopa but its response is very much less. The author uses amantadine as additional treatment in patients who tolerate only sub-optimal dosage of levodopa. It is very well tolerated by most patients although the benefits seem to be greatest when it is first used and decline within 1 to 3 months. Side effects include confusion, restlessness and insomnia. What is the current role of stereotactic thalamotomy in the treatment of Parkinsonism? The patient with severe unilateral tremor who has failed to respond to medical treatment may be greatly improved symptomatically by thalamotomy. In such cases the risk of morbidity, which is about 5%O, is justified. Surgery relieves tremor and has some effect on rigidity. It has no effect on hypokinesia. Gait disturbance, dysarthria and dysphonia may be made worse by surgical intervention especially where bilateral thalamotomy is performed. Dementia, arteriosclerosis, hypertension and incontinence are all contraindications to surgery.
Levodopa and related drugs, anticholinergics and surgery are the specific treatments for the symptoms of Parkinsonism but there are other less specific treatments that are sometimes indicated in addition.
Beta-blockers such as propranolol may be occasionally beneficial in the relief of parkinsonian tremor. Depression is a very common symptom in Parkinson's disease to such an extent that it is regarded by some as part of the syndrome. Tricyclic antidepressants have an anticholinergic effect and are consequently doubly valuable in a patient with significant depression. Excessive salivation may require additional therapy with atropine or probanthine. The treatment of insomnia and constipation is frequently of great importance. Physiotherapy may be of great value in patients who are being started on treatment; it may also be useful in the case with painful complications of immobility. But physiotherapy should be limited to courses lasting up to three months with the patient responsible subsequently for maintaining physical exercise under his own initiative.
Perhaps more important than anything in treating these patients is giving them psychological support and encouragement. Most patients should be told the diagnosis and advised that the disease will not 'go away' nor can it be 'cured'. But it should be emphasized that much can be done for the symptoms both immediately and if the disease progresses. The patient must of course be encouraged to retain his independence and not allow relatives to help him just to save time. He must retain his interests in hobbies and reading and should be as physically active as possible. An active, hopeful approach is most important in counteracting the depression and lethargy that are so much part of the disease.
The recent history of the treatment of Parkinsonism has been one of rapid change and there is every indication of further advances in treatment in the future. For example synthetic dopa-like drugs are becoming available and the first that is being marketed, albeit for different indications, is bromocriptine. A trial of this drug has recently been completed comparing it with levodopa. In the majority of patients it is less effective even at optimal dosage and the central side effects-confusion and memory disturbance-were worse than with levodopa. However, a few patients tolerated bromocriptine better than they did levodopa and in this trial there were no patients who developed abnormal movements or 'on-off' attacks while on treatment with bromocriptine alone-even where these side effects had been troublesome with levodopa. Bromocriptine is probably the most promising synthetic dopamine agonist currently available but there is no doubt that many other similar compounds will be developed in the near future. The hope is that such drugs will allow the separation of therapeutic effect from central toxic effect and particularly enable us to treat Parkinson's disease without the emergence of the dyskinetic side effects or the 'on-off' reaction.
Similarly there has been recently renewed interest in the potentiating effect on levodopa of synthetic melanocyte-inhibitory factor.
Already improvements in the quality of life and longevity have been achieved by advances in the treatment of this disease which have been introduced during the last ten years. There is every reason to hope that similar advances in the next decade will lead to further improvement in the treatment of this common disabling disease.
